Literature DB >> 1284103

Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis.

B Wüthrich1, M K Kägi, H Joller-Jemelka.   

Abstract

Levels of soluble IL-2 receptors, IL-6, soluble CD23, soluble CD14 and ECP (eosinophilic cationic protein) were measured as markers of T-cell, B-cell, monocyte and eosinophilic leucocyte activation in 26 patients with atopic dermatitis (AD) on admission to (A) and at discharge from (D) the Department of Dermatology in Zurich. The serum levels of sIL-2R, IL-6, sCD23, sCD14 and ECP were significantly elevated in AD patients in comparison with the normal values of healthy donors. A significant decrease in sIL-2R (p = 0.0093) and in sCD14 (p = 0.0134) levels was demonstrated between A and D, correlating with the improvement in the skin intensity score (SIS). In addition, a significant correlation of the sCD14 levels and the SIS at A was demonstrated (p = 0.0415). These results also incriminate monocytes in the pathogenesis of AD, indicating that, besides sIL-2R and ECP, SCD14 could also be a possible marker for the disease activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1284103     DOI: 10.1007/bf00372036

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  21 in total

1.  Levels of soluble interleukin-2 receptors correlate with the severity of atopic dermatitis.

Authors:  B Wüthrich; H Joller-Jemelka; U Helfenstein; P J Grob
Journal:  Dermatologica       Date:  1990

2.  Eosinophil cationic protein in sera of patients with atopic dermatitis.

Authors:  A Kapp; W Czech; J Krutmann; E Schöpf
Journal:  J Am Acad Dermatol       Date:  1991-04       Impact factor: 11.527

3.  Serum interleukin-2 receptor levels in atopic dermatitis.

Authors:  B Wüthrich; H J Joller-Jemelka; P J Grob
Journal:  Dermatologica       Date:  1989

4.  Eosinophilic cationic protein (ECP) in skin disorders.

Authors:  L Juhlin; P Venge
Journal:  Acta Derm Venereol       Date:  1991       Impact factor: 4.437

Review 5.  Atopic dermatitis.

Authors:  J M Hanifin
Journal:  J Allergy Clin Immunol       Date:  1984-02       Impact factor: 10.793

6.  Serum IgE in atopic dermatitis: relationship to severity of cutaneous involvement and course of disease as well as coexistence of atopic respiratory diseases.

Authors:  B Wüthrich
Journal:  Clin Allergy       Date:  1978-05

7.  Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes.

Authors:  R M Grossman; J Krueger; D Yourish; A Granelli-Piperno; D P Murphy; L T May; T S Kupper; P B Sehgal; A B Gottlieb
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis.

Authors:  A Kapp; A Piskorski; E Schöpf
Journal:  Br J Dermatol       Date:  1988-12       Impact factor: 9.302

9.  Mononuclear cell-bound CD23 is elevated in both atopic dermatitis and psoriasis.

Authors:  K M Müller; M Röcken; D Joel; J Y Bonnefoy; J H Saurat; C Hauser
Journal:  J Dermatol Sci       Date:  1991-03       Impact factor: 4.563

10.  Interleukin 2: the molecule and its function.

Authors:  R J Robb
Journal:  Immunol Today       Date:  1984-07
View more
  10 in total

1.  Increased levels of circulating soluble CD14 in Kawasaki disease.

Authors:  S Takeshita; K Nakatani; H Tsujimoto; Y Kawamura; H Kawase; I Sekine
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities.

Authors:  Cristian Palmiere; Michele Mussap; Daniel Bardy; Francesco Cibecchini; Patrice Mangin
Journal:  Int J Legal Med       Date:  2012-12-22       Impact factor: 2.686

3.  Soluble CD14 activates monocytic cells independently of lipopolysaccharide.

Authors:  R Landmann; S Link; S Sansano; Z Rajacic; W Zimmerli
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

4.  Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with bacterial diarrhea in US and Canadian travelers to Mexico.

Authors:  Jamal A Mohamed; Herbert L DuPont; Jose Flores; Himaja Palur; Parvathy Nair; Zhi-Dong Jiang; Dongchuan Guo; Jaime Belkind-Gerson; Pablo C Okhuysen
Journal:  Clin Infect Dis       Date:  2011-06       Impact factor: 9.079

5.  Soluble macrophage biomarkers indicate inflammatory phenotypes in patients with knee osteoarthritis.

Authors:  Hikmat N Daghestani; Carl F Pieper; Virginia B Kraus
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

6.  Soluble CD14 mediates lipopolysaccharide-induced intercellular adhesion molecule 1 expression in cultured human gingival fibroblasts.

Authors:  J Hayashi; T Masaka; I Saito; I Ishikawa
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

7.  Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma.

Authors:  Mi Zhou; Joseph L Wiemels; Paige M Bracci; Margaret R Wrensch; Lucie S McCoy; Terri Rice; Jennette D Sison; Joseph S Patoka; John K Wiencke
Journal:  Cancer Res       Date:  2010-08-18       Impact factor: 12.701

Review 8.  Soluble CD14: role in atopic disease and recurrent infections, including otitis media.

Authors:  Karin C Lødrup Carlsen; Berit Granum
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

9.  Clinical proteomics identifies urinary CD14 as a potential biomarker for diagnosis of stable coronary artery disease.

Authors:  Min-Yi Lee; Chun-Hao Huang; Chao-Jen Kuo; Chen-Lung Steve Lin; Wen-Ter Lai; Shyh-Horng Chiou
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

10.  Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis.

Authors:  David R Beers; Weihua Zhao; Daniel W Neal; Jason R Thonhoff; Aaron D Thome; Alireza Faridar; Shixiang Wen; Jinghong Wang; Stanley H Appel
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.